3 Reasons to Sell Sequenom Today

Watch stocks you care about

The single, easiest way to keep track of all the stocks that matter...

Your own personalized stock watchlist!

It's a 100% FREE Motley Fool service...

Click Here Now

The turmoil in the markets makes it too easy to justify selling any stock these days. Yet, while panic never helps investors, it's still a good idea to play devil's advocate with investments.

Consider genetic diagnostics firm Sequenom (Nasdaq: SQNM  ) . Though its novel genetic test hold tremendous promise, you'll find more than a few of the 662 Motley Fool CAPS members weighing in on the company offer reasons to be bearish today.

Here at the Motley Fool, we like to consider both the good and bad sides of an investment, so in this article, so I'm highlighting three of the main bearish arguments on Sequenom today. Be sure to read the bullish case, as well, and then weigh in with your own comments below, or rate Sequenom in CAPS.                                              

1. Legal mess
Due to ongoing litigation, investigations and legal expenses regarding the mishandling of clinical data for its prized prenatal Down syndrome test, Sequenom recently said it won't be offering any guidance for the next couple of quarters. That move leaves investors to take a shot in the dark about where its financials are headed. While companies like Mahindra Satyam (NYSE: SAY  ) have survived legal debacles, some investors see too much uncertainty surrounding Sequenom's situation.

2. Short cash string
Unlike larger peers such as Gilead Sciences (Nasdaq: GILD  ) and Bristol-Myers Squibb (NYSE: BMY  ) that generate billions in free cash flow, Sequenom has a history of recurring losses and expects to continue burning cash for the foreseeable future. In its third-quarter earnings report, the company stated its concerns about having enough money to make it through 2010 if it maintained the same spending levels, which has some investors not sticking around to find out whether the company will make it.                                                                                                                         

3. It's a gamble
Even many of the CAPS members who think that Sequenom will outperform the market recognize that their pick is a gamble more than an investment. Sequenom's stock has been largely driven by potential, similar to other biotech players Onyx Pharmaceuticals (Nasdaq: ONXX  ) , Exelixis (Nasdaq: EXEL  ) , and Seattle Genetics (Nasdaq: SGEN  ) . And some investors don't have the stomach to hold on to the large swings in share price.

To see details of what CAPS members are saying now about Sequenom, just click on over to Motley Fool CAPS and have a look -- or add your own thoughts directly to this story in the comments box below.

The Motley Fool Stock Advisor service looks for companies with strong management poised to beat the market over the long haul. To see all the stocks that have helped Tom and David Gardner beat the market by 50 points on average, take a free 30-day trial.

Fool contributor Dave Mock  votes three to be the number of the day. He owns no shares of companies mentioned here. Exelixis is a Rule Breakers selection. The Fool owns shares of Exelixis. The Fool's disclosure policy sheepishly admits to running up a four-figure cell phone bill text voting for American Idol.

Read/Post Comments (0) | Recommend This Article (10)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 1086355, ~/Articles/ArticleHandler.aspx, 10/23/2016 6:42:09 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 1 day ago Sponsored by:
DOW 18,145.71 -16.64 -0.09%
S&P 500 2,141.16 -0.18 -0.01%
NASD 5,257.40 15.57 0.30%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

12/31/1969 7:00 PM
SQNM $0.00 Down +0.00 +0.00%
Sequenom CAPS Rating: **
BMY $50.02 Down -0.34 -0.68%
Bristol-Myers Squi… CAPS Rating: ****
EXEL $11.56 Down -0.18 -1.53%
Exelixis CAPS Rating: ****
GILD $74.29 Down -0.02 -0.03%
Gilead Sciences CAPS Rating: *****
ONXX.DL $0.00 Down +0.00 +0.00%
Onyx Pharmaceutica… CAPS Rating: **
SAYCY.DL $2.64 Down +0.00 +0.00%
Satyam Computer Se… CAPS Rating: ****
SGEN $50.83 Down -0.77 -1.49%
Seattle Genetics CAPS Rating: ****